Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

s target of p<0.05), as previously reported. This was the second primary endpoint.

Implications of these additional data

The significantly reduced sedation seen with M6G provides additional support to our view that M6G is equivalent to morphine in controlling pain but has a superior side-effect profile. This should give clinicians more confidence that patients are less likely to experience sedation with M6G. Sedation is one of the side effects of most concern associated with agents like morphine, along with respiratory depression.

The additional analysis announced today will be used to improve further the designs of the planned US Phase III clinical studies by targeting higher risk patient groups and surgical procedures where the clinical benefits from M6G will be maximised.

Neil Clark, Chief Executive of CeNeS, commented: "This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery - an additional growing market to the current focus on hospital based post-operative pain.

"It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

Post Your Comments:
(Date:11/6/2009)...ire/ -- , - Trial Will Compare NXL103 Wit...f Multi-Resistant Staphylococcus Aureus (MRSA) Inf...tical company focused on the discovery and,develop... significant global,problem of microbial resistanc...ibacterial NXL103 (flopristin/linopristin), has st...
(Date:11/5/2009)... Transcept Pharmaceutica...cal company focused on the development and commerc...portant therapeutic needs in the field of neurosci...eleconference with management to discuss third qua...12, 2009, at 5:00 p.m. Eastern Standard Time. Fin...
(Date:11/5/2009)...ewswire/ -- Renee Cobos, MD, a board certified der...at the University of California, Irvine, announced...us results with Thermage CPT®. The updated sy...ntouring, features a new vibrating hand piece that... comfort. ,, "Thermage has always been popular...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2Good news for some hard to treat hepatitis C patients 49004 1Good news for some hard to treat hepatitis C patients 49004 2MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE a Global Phase 2 3 Clinical Trial of Teplizumab in Type 1 Diabetes 4596 1MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE a Global Phase 2 3 Clinical Trial of Teplizumab in Type 1 Diabetes 4596 2MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE a Global Phase 2 3 Clinical Trial of Teplizumab in Type 1 Diabetes 4596 3MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE a Global Phase 2 3 Clinical Trial of Teplizumab in Type 1 Diabetes 4596 4A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 1A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 2A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 3
...estive Disease Week data highlight effects of AMIT...C, SAN DIEGO, May 18 New study results indicated...cg lead to significant relief,of overall symptoms ...-C).,These results were presented at Digestive Dis...onal meeting of digestive disease specialists., "...
... that Adding Singulair to Advair Offers no Additio...Control, RESEARCH TRIANGLE PARK, N.C. and TORONTO...oth asthma and allergic rhinitis, or seasonal alle...n when treated with Advair,Diskus(R) (fluticasone ...mpared with Singulair (montelukast sodium). The re...
Other Medicine Technology:New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3
(Date:11/7/2009)...ted for Life Action endorses a key vote today on t...r-Dahlkemper-Lipinski-Smith Amendment, an Amendmen...tion in health care reform. ,, Americans United fo...est said, "Americans United for Life Action strong...kemper-Lipinski-Smith Amendment to prohibit aborti...
(Date:11/7/2009)...youth will rebel, expert says , , SATURDAY... to behave badly if their parents expect them to, ... they are simply being realistic might actually co...uchanan, a psychology professor at Wake Forest Uni...ersity news release. "Negative expectations on the...
(Date:11/7/2009)...23-25th marked the 12th annual tournament bringing...tle against pediatric cancer. Stephen Updegraff, ...for many years. , St. Pet...end of October 23-25 marked the 12th annual tourn...ghting the battle against pediatric cancer– ...
(Date:11/7/2009)...lsquo;sweatox’ or ‘Boytox’, the ...nti-ageing jab ‘Breastox’ – or b...e;colletage, can reduce the appearance of wrinkles...easts, leaving smoother, younger-looking skin. , ...- Transform, the UK’s largest group of cosm...
(Date:11/6/2009)...UVER, Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pha...ced that it will report financial results for the ...ing of Monday, November 9, 2009. Cardiome will hol...ern (6:00am Pacific) on that day to discuss the re...al 416-695-7806 or 888-789-9572 and reference conf...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:UK Boobs Get a Boost with 'Breastox' 2Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3
...SBURG, Pa., March 28 Governor Edward G.,Rendell t...hysicians, which,explains the March 31 deadline fo...re Provider:, In December, I wrote informing you ... of thousands of uninsured,Pennsylvanians., As yo...
...THE GOVERNMENT CURB AN OVERLY AGGRESSIVE VACCINATI... Mo., March 28 Parents of children who,regressed ...g cautious,optimism that government health officia...by reported details of a conference call held earl...
...LO, N.Y., March 28 Dr. Eaton E.,Lattman, currentl...anvyl,Krieger School of Arts and Sciences at Johns...f Executive Officer and Executive Director of the,... has degrees from Harvard and JHU and at JHU has s...
...ase in specific white blood cells could warn docto...March 28 (HealthDay News) -- Researchers at Temple...er that denotes the progression of the virus that ... (HIV), according to a study published in the Marc...
...er, patients stay on the new medications longer, s... News) -- Newer, so-called second-generation antip...ridol in treating a first episode of schizophrenia...study authors said. , "When we compared newer drug...
...w Special Video and Feedback on Web Site -, PHOEN...munized, TriWest Healthcare Alliance,s network doc...nd their families with peace of mind during the,go...ns its TRICARE beneficiaries in thanking and showi...
Other Medicine News:Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:Biomarker May Signal HIV Progression 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:TriWest Recognizes Contributions of TRICARE Docs to Military Community on Doctors' Day 2
...dth of infectious disease ELISA products make us a...ls for faster integration into the busy laboratory...creased reliability and run-to-run consistency. Ou...detection assays for a wide range of serological a...
...dth of infectious disease ELISA products make us a...ls for faster integration into the busy laboratory...creased reliability and run-to-run consistency. Ou...detection assays for a wide range of serological a...
...dth of infectious disease ELISA products make us a...ls for faster integration into the busy laboratory...creased reliability and run-to-run consistency. Ou...detection assays for a wide range of serological a...
...dth of infectious disease ELISA products make us a...ls for faster integration into the busy laboratory...creased reliability and run-to-run consistency. Ou...detection assays for a wide range of serological a...
Medicine Products: